Cytokines in serum in relation to future non-Hodgkin lymphoma risk: Evidence for associations by histologic subtype

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 913-922

  Edlefsen, Kerstin L ^a   Martínez Maza, Otoniel ^b,c   Madeleine, Margaret M ^d,e   Magpantay, Larry ^b   Mirick, Dana K ^d   Kopecky, Kenneth J ^d   Lacroix, Andrea Z ^d,e,f   De Roos, Anneclaire J ^d,g  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DREXEL UNIVERSITY   (United States)

Author keywords

cohort studies; cytokines; epidemiology; non Hodgkin lymphoma

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MILODISTIM; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD ANALYSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IL10 GENE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TNF GENE;

COHORT STUDIES; CYTOKINES; EPIDEMIOLOGY; NON-HODGKIN LYMPHOMA;

AGED; ALLELES; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INTERLEUKIN-10; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902269877     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28724     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris NL, et al., eds. The WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon, France: IARC, 2008.
2. Rabkin CS, Engels EA, Landgren O, et al. Circulating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. Am J Hematol 2011; 86: 875-8.
3. Husain A, Roberts D, Pro B, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 2007; 110: 809-15.
4. Spinelli JJ, Lai AS, Krajden M, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008; 122: 630-3.
5. Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004; 111: 76-80.
6. Dias C, Martins J, Dias G, et al. B-cell lymphomagenesis in autoimmune diseases: the missing links. Discov Med 2012; 13: 417-24.
7. Christopoulos P, Pfeifer D, Bartholome K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117: 3836-46.
8. Morrison VA,. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009; 9: 365-70.
9. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171: 267-76.
10. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27-38.
11. Saberi Hosnijeh F, Krop EJ, Scoccianti C, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2010; 19: 1577-84.
12. Gu Y, Shore RE, Arslan AA, et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control 2010; 21: 1323-33.
13. Purdue MP, Lan Q, Bagni R, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 2011; 71: 4898-907.
14. Conroy SM, Maskarinec G, Morimoto Y, et al. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2013; 22: 337-47.
15. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998; 19: 61-109.
16. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000.
17. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695-708.
18. Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004; 112: 1691-6.
19. Moschandreas DJ, Karuchit S, Kim Y, et al. On predicting multi-route and multimedia residential exposure to chlorpyrifos and diazinon. J Expo Anal Environ Epidemiol 2001; 11: 56-65.
20. Helsel DR,. More than obvious: better methods for interpreting nondetect data. Environ Sci Technol 2005; 39: 419A-23A.
21. Rubin DB,. Multiple Imputation for Nonresponse in Surveysed. New York: Wiley, 1987.
22. De Roos AJ, Mirick DK, Edlefsen KL, et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 2012; 72: 4733-43.
23. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
24. Boussiotis VA, Nadler LM, Strominger JL, et al. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 1994; 91: 7007-11.
25. Younes A, Aggarwall BB,. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003; 98: 458-67.
26. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-9.
27. Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007; 67: 5042-54.
28. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
29. Burdin N, Van, Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995; 154: 2533-44.
30. Muti G, Mancini V, Ravelli E, et al. Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Leuk Lymphoma 2005; 46: 1397-407.
31. Cortes J, Kurzrock R,. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26: 251-9.
32. Breen EC, Boscardin WJ, Detels R, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003; 109: 119-29.
33. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
34. Hamoudi RA, Appert A, Ye H, et al. Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010; 24: 1487-97.
35. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575-83.
36. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009; 360: 659-67.
37. Garaud S, Morva A, Lemoine S, et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011; 186: 4835-44.